未找到相关数据
Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
被引：7
作者：
Xia, Yongxiang
Wang, Ping
Pu, Liyong
Qian, Xiaofeng
Cheng, Feng
Wang, Ke
Zhang, Chuanyong
Li, Donghua
Li, Xiangcheng
Zhang, Feng
Zhao, Jie
Li, Si
Xi, Wenjing
Wang, Xuehao
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, Nanjing, Peoples R China
[2] Jiangsu Simcere Diagnost Co Ltd, Nanjing Simcere Med Lab Sci Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Dept Med, Nanjing, Peoples R China
[3] Jiangsu Simcere Diagnost Co Ltd, Nanjing Simcere Med Lab Sci Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Bioinformat Dept, Nanjing, Peoples R China
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4082
引用
收藏
页数：2
相关论文